# TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

> **NCT06589830** · PHASE2 · RECRUITING · sponsor: **Suzhou Teligene Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Advanced Colorectal Cancer

## Interventions

- **DRUG:** TL938 Capsules
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT06589830
- **Lead sponsor:** Suzhou Teligene Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589830, "TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06589830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*